Malignant Hyperthermia: Crisis Dosing and the Family Downstream of It
A college wrestler crashes into a fulminant MH crisis under his first general anesthetic. Three weeks later his mother, a confirmed RYR1 carrier, is scheduled for an elective cholecystectomy — the same disease, a completely different pharmacologic question.
T.O., a 19-year-old man, is three sets into his sophomore wrestling season when a torn ACL sends him to the OR for reconstruction — his first general anesthetic. Forty minutes after induction with sevoflurane and succinylcholine, his end-tidal CO2 climbs from 38 to 71 mmHg despite an unchanged ventilator setting, his masseter has locked tight enough that the surgical team notices before the monitor does, and his temperature is rising through 39.2°C on its way somewhere worse. His heart rate is 148 and his urine has gone the color of dark tea — myoglobin, not blood.
Malignant hyperthermia is a pharmacogenetic crisis, not a fixed-dose problem: a mutated RYR1 receptor lets the sarcoplasmic reticulum dump calcium uncontrollably once a triggering agent is on board, and the hypermetabolic cascade that follows keeps running until dantrolene actually uncouples that release, not until a protocol-card dose has been given. His initial 2.5 mg/kg bolus brings his ETCO2 down to 54 within eight minutes — real movement, but not resolution — and his CK, drawn in the same window, comes back at 18,000 U/L, confirming the degree of muscle breakdown already in progress before anyone in the room had a diagnosis to act on.
Nobody in the family knew this was coming. The uncle's decades-old "bad reaction" was never formally worked up, the kind of half-remembered family story that reads as anecdote until a second relative's anesthetic reproduces it precisely enough to become data instead. T.O.'s own case is being managed with the newer nanocrystalline formulation, and the arithmetic of that choice is the reason the room is not further behind than it is: 250 mg reconstitutes in 5 mL of sterile water, where the older preparation delivers 20 mg per vial and needs 60 mL for each one. Reaching the same 250 mg the old way means twelve and a half vials and something near 750 mL to mix — which is why MHAUS stocks three vials of the new formulation against thirty-six of the old. Registry figures put the median dose actually used in a crisis at 5.9 mg/kg, better than twice the 2.5 mg/kg already in him, so the vials still to come are not a hypothetical and reconstitution time is part of the clock he is on.
Redose now — 2.5 mg/kg again, and keep going every five minutes until the ETCO2, temperature, and rigidity are actually resolving, not just improved. Dantrolene's own dosing ceiling in the MHAUS crisis protocol is 10 mg/kg, and that number exists because most crises resolve under it, not because 10 is a hard biological limit — if he needs more, he gets more.
I'd rather explain a large cumulative dose to hepatology next week than explain to this family why we stopped at a number instead of a response.
His ETCO2 already dropped from 71 to 54 off one bolus — that's real signal, not noise. Dantrolene at cumulative doses well above 10 mg/kg produces genuine hepatotoxicity and profound generalized muscle weakness that can itself complicate extubation and ventilatory recovery. I'm not arguing for undertreatment; I'm arguing for redosing to the actual trend on this monitor, not to a number we picked before seeing how he responds to the first dose.
"If he needs more, he gets more" isn't in dispute — the question is whether we're re-dosing to a genuinely stalled crisis or to residual findings that are already resolving on their own trajectory.
Both of you are actually describing the same dosing rule — redose to effect, watch the trend — you're just disagreeing about whether his trend already counts as resolving. The question that actually divides us is downstream: Burkman's analysis of North American MH registry cases put recrudescence — a second crisis after apparent resolution — at about one in five, and the variables it associated with relapse are the three he happens to carry: muscular body habitus, a high peak temperature, and a long interval from induction to first recognized sign. That argues for the full 24-hour ICU monitoring window at minimum, not a shortened one just because tonight's numbers look better by midnight.
Agreed: a second 2.5 mg/kg dantrolene bolus given, cumulative dose held at 5 mg/kg once ETCO2, temperature, and rigidity all showed sustained (not single-reading) improvement over the following twenty minutes. He was transitioned to a propofol-based maintenance anesthetic for the remainder of a shortened procedure and transferred to the ICU intubated.
Not agreed, and carried forward explicitly to the ICU handoff: whether his specific recrudescence risk (muscular habitus, peak temperature, and the diagnostic delay) argues for extending observation past the standard 24-hour window. The critical care physician wanted a firm 24-hour endpoint pending repeat CK and a stable exam; the pharmacologist wanted that decision revisited against the trend at hour 24 rather than fixed in advance.
Renata S., a 46-year-old woman, is T.O.'s mother, scheduled for a laparoscopic cholecystectomy she'd already delayed twice before her son's crisis forced the family's hand on genetic testing. She works as a dental hygienist, has no prior surgical history of her own, and confirmed RYR1-positive on the panel drawn the week after T.O.'s ICU discharge — asymptomatic her entire life, unaware until three weeks ago that she carried the same mutation.
The genetic counselor who delivered her results also tested T.O.'s younger sister, still negative, and flagged Renata's own mother — the source of the family's uncle-side history, it turns out, once the pedigree was actually drawn out — as a candidate for testing she has so far declined. Renata describes herself as "the calm one" in most family crises, but admits this consultation is the first time she's asked an anesthesiologist more questions than the anesthesiologist has asked her, a detail the team reads less as anxiety than as a patient who has just spent three weeks learning more pharmacogenetics than most people ever do and wants her own plan to reflect it.
A trigger-free anesthetic — propofol-based TIVA, no volatile agent, non-depolarizing neuromuscular blockade only if needed, an MH cart and dantrolene physically staged in the room — removes essentially all of the acute risk her son's case demonstrated so vividly. The genuinely contested question is prophylactic dantrolene given before induction, on the theory that some margin against a triggering exposure that shouldn't happen anyway is better than none. MHAUS's own current position statement holds that prophylactic dantrolene is not routinely recommended when a trigger-free technique is achievable — not because the drug doesn't work, but because a genuinely trigger-free plan already removes the mechanism the drug exists to block, and dantrolene itself carries real dose-dependent risk (muscle weakness, hepatic transaminase elevation) that a truly asymptomatic patient doesn't need to absorb for a threat that isn't present in the room.
A trigger-free TIVA plan with dantrolene staged and full ETCO2/temperature monitoring from induction is the actual standard of care here — and the MHAUS position statement is explicit that prophylactic dantrolene is not routinely recommended on top of it. The drug's job is blocking a cascade that a genuinely trigger-free anesthetic doesn't start in the first place.
I understand the position statement, and I'm not disputing the pharmacology — but this isn't an abstract population three weeks after she watched her own son nearly die under anesthesia. A prophylactic dose is a real, tangible thing this family can ask for, and I don't think "not routinely recommended" is the same as "contraindicated" or "without benefit."
And I'd note what the position statement is actually built on: expert consensus and the absence of demonstrated benefit, not a randomized trial in asymptomatic carriers — there isn't one, because the event rate under a trigger-free technique is too low to power. "Not routinely recommended" in that setting means "no one has shown it helps," which is not the same claim as "we have shown it doesn't."
Both of you are arguing about a margin that isn't where the real protection lives. The variable that actually determines whether a crisis becomes fatal is time-to-dantrolene once symptoms start, not whether a dose was already on board before induction. What changes her outcome is dantrolene physically in the room, ETCO2 and temperature monitoring running from the first minute, and staff who know the crisis protocol cold — readiness, not prophylaxis. That's the thing worth spending the visit on.
Agreed: full trigger-free TIVA technique, dantrolene physically staged in the OR with the MH cart, continuous ETCO2 and core temperature monitoring from induction, and a pre-briefed team walked through the crisis protocol before she was ever brought back. No prophylactic dantrolene given.
Not fully agreed, and left open for the family to revisit before the day of surgery: whether a single prophylactic dose still has a place given the family's own risk tolerance, independent of the population-level position statement. The primary care physician offered to relay whatever the family ultimately decided; the anesthesiologist agreed to honor a genuine, informed request either way, while standing by the position statement as the default plan.